Salarius Pharmaceuticals is a clinical stage oncology biotech developing our lead asset, seclidemstat, for patients that need them most. Seclidemstat utilizes a novel approach to target a validated therapeutic target. It is being studies in two ongoing clinical trials with readouts anticipated in late 2020/early 2021.
Ticker:
SLRX
Exchange:
Nasdaq-CM
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
Oncology
Lead Product in Development:
SP-2577 (seclidemstat)
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
